Arcturus therapeutics reports new data demonstrating neutralizing antibody immune response to the sars-cov-2 omicron variant from arct-154 and arct-165 booster clinical trial

San diego--(business wire)---- $arct #clinicaltrial--arcturus reports data demonstrating neutralizing antibody immune response to the sars-cov-2 omicron variant from arct-154 and arct-165 booster trial

ARCT Ratings Summary

ARCT Quant Ranking